Loading...
Organon partners with Huya to identify and develop Chinese biopharmaceuticals
Collaboration looks for opportunities to expand the Organon biotech research programs and facilitate links with China's biotech industry
11-Jan-2007
Advertisement
Organon announced that it has signed a collaboration agreement with HUYA Bioscience International, LLC, (HUYA) to search for new, proprietary biopharmaceuticals or pharmaceutical compounds. As part of this collaboration, Organon has acquired an equity interest in HUYA.
HUYA, with offices in San Diego and Shanghai, identifies, licenses and develops Chinese drug candidates for commercialization in Western markets. Under the collaboration agreement, HUYA will support Organon in the sourcing and development of pharmaceutical or biopharmaceutical compounds in three specific therapeutic areas.
No financial details of the transaction were disclosed.
Other news from the department business & finance
Most read news
More news from our other portals
Last viewed contents
OncoGenex Adds David V. Smith to the Board of Directors
Crucell Announces Large Scale Quinvaxem Vaccinations in Ethiopia
CyGenics CEO Reappointed BioSingapore Chairman
Miriam Monge to Join Sartorius Stedim Biotech as Director
